Produktbild: Drug Discovery Stories

Drug Discovery Stories From Bench to Bedside

214,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Portrait

Professor Bin Yu obtained his PhD degree from Zhengzhou University and University of Cambridge and currently is a professor of medicinal chemistry at School of Pharmaceutical Sciences, Zhengzhou University. His research interests focus on chemistry driven drug discovery for novel therapeutics. To date, he has published over 120 papers in international high-impact peer-reviewed journals including Journal of Medicinal Chemistry, Organic Letters, Pharmacology & Therapeutics, Journal of Hematology & Oncology, Drug Discovery Today, Acta Pharmaceutica Sinica B, etc., 10 of them were published in journal with impact factor (IF) >10.

Peng Zhan obtained his B.S. degree from Shandong University, China, in 2005. He then earned his M.S. and Ph.D. degrees in medicinal chemistry from Shandong University in 2008 and 2010. He subsequently joined Shandong University as a Lecturer (2010-2012). From 2012 to 2014, he worked as a postdoctoral fellow funded by Japan Society for the Promotion of Science. He is currently a full professor in the Department of Medicinal Chemistry, Shandong University. His research interests involve the discovery of novel anti-viral (HIV, HBV, influenza, coronavirus, etc.), anti-gout, and anti-cancer agents based on rational drug design and combinatorial chemistry approaches. He also co-edited six books published by People's Medical Publishing House and Springer Nature, respectively and granted 50 patents (30 of them licensed). He currently serves as advisory editorial board member of Journal of Medicinal Chemistry.

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

18.10.2024

Herausgeber

Bin Yu + weitere

Verlag

Elsevier

Seitenzahl

710

Maße (L/B/H)

27,7/21,1/3,6 cm

Gewicht

1837 g

Sprache

Englisch

ISBN

978-0-443-23932-8

Portrait

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

18.10.2024

Herausgeber

Verlag

Elsevier

Seitenzahl

710

Maße (L/B/H)

27,7/21,1/3,6 cm

Gewicht

1837 g

Sprache

Englisch

ISBN

978-0-443-23932-8

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: gpsr@libri.de

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

Die Leseprobe wird geladen.
  • Produktbild: Drug Discovery Stories
  • Section 1: Drug discovery techniques and Strategies
    1. Artificial Intelligence in Early Stages of Structure-Based Drug Discovery
    2. Target-based vs Phenotypic drug discovery: Opportunities and challenges with evidence-based application
    3. Hit Discovery from DNA-Encoded Chemical Libraries
    4. Discovery of Lead Compounds from Pseudo-Natural Macrocycles Enabled by Modular Biomimetic Strategy
    5. Macrocyclization strategy in kinase drug discovery
    6. Cobalt catalyzed C-H functionalization for the synthesis of chiral heterocyclic molecules
    7. Advancing Proteolysis Targeting Chimeras towards Clinical Drug Developments
    8. A future battle, small molecule drugs for cancer stem cell targeted therapy
    9. Stem cell therapies for combating emerging and re-emerging viral infections
    10. Targeting Autophagy with Pharmacological Small-Molecules to Treat Human Diseases
    11. Interferons in human papillomavirus infection: antiviral effectors or immunopathogenic role?
    12. Selenium and small molecules: a symbiotic partnership
    13. Novel Combinations of CD33-Targeted Immunotherapies
    14. Novel payloads of antibody-drug conjugates
    15. Antibody-Drug Conjugates (ADCs): A New Generation of Cancer Vaccines
    16. mRNA Vaccines: The Next Frontier in Disease Prevention
    17. Unravelling the drying techniques of protein biopharmaceuticals

    Section 2: Drug discovery case studies
    18. Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatmet of multidrig-resistant HIV infections
    19. Nirmatrelvir, SIM0417, and RAY1216: Potent and Selective SARS-CoV-2 Main Protease Inhibitors for the Potential Treatment of COVID-19
    20. ARV-110: An Androgen Receptor Degrader in the Treatment of Metastatic Castration-Resistant Prostate Cancer
    21. Darolutamide: An Androgen Receptor Antagonist for the Treatment of Prostate Cancer
    22. Palbociclib, Ribociclib, and Abemaciclib: Potent and Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer
    23. Zanubrutinib: A breakthrough in cancer therapy targeting BTK, originating from China and benefiting the global community
    24. Discovery of FT-2102 (olutasidenib), an inhibitor of mutant isocitrate dehydrogenase 1, for treatment of relapsed or refractory acute myeloid leukemia
    25. Ziftomenib (KO-539): A Potent and Selective Menin Inhibitor for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
    26. Pulrodemstat (CC-90011): A Potent, Selective, and Reversible LSD1 Inhibitor
    27. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
    28. Verquvo, a First-in-Class Soluble Guanylate Cyclase (sGC) Stimulator for the Treatment of Heart Failure
    29. Tafamidis: a Transthyretin Stabilizer for Rare Cardiac Amyloidosis
    30. Oliceridine (TRV-130): A Biased Agonist of the ¿ Opioid Receptor as a Novel Analgesic
    31. Sotyktu (Deucravacitinib): The First TYK2 Inhibitor Approved for the Treatment of Psoriasis
    32. Bexagliflozin: A SGLT-2 Inhibitor as Antidiabetic Drug Derived From Phlorizin
    33. Antidiabetic Drugs Targeted PPAR¿: From Full Agonists to Selective Modulators
    34. Pretomanid: an antibiotic used for the treatment of multidrug-resistant tuberculosis
    35. Lecanemab (Leqembi): An Amyloid Beta Monoclonal Antibody Approved for the Treatment of Alzheimer's Disease